# Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma

> **NCT07652138** · PHASE1 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 18 (estimated)

## Conditions studied

- Multiple Myloma
- Newly Diagnosed Multiple Myeloma (NDMM)

## Interventions

- **DRUG:** BCMA/CD19-targeted allogeneic CAR-T

## Key facts

- **NCT ID:** NCT07652138
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-11-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07652138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07652138, "Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07652138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*